We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




BRIC Countries Outperform Rest of the World in IVD Sales Growth

By LabMedica International staff writers
Posted on 27 Jun 2011
The rate of growth for diagnostic instrumentation, product, and reagent sales for Brazil, Russia, India, and China (dubbed the BRIC nations) is double the six percent growth rate projected for worldwide in vitro diagnostics (IVD) sales.

In BRIC nations IVD sales are expected to grow from US $2.9 billion in 2009 to $5 billion in 2014, which represents a compound annual growth rate (CAGR) of 12%. More...
The market in these countries is dominated by companies such as Roche (Basel, Switzerland), Abbott (Des Plaines, IL, USA), Siemens (Munich, Germany), and Beckman Coulter (Fullerton, CA, USA). Domestic companies such as Transasia (Mumbai, India), Horiba (Kyoto, Japan), and Mindray (Shenzhen, China) have taken the distribution of IVD products from urban areas to the rural areas in their respective markets. Incumbent companies tend to provide a host of routine tests.

It is expected that as the IVD demand in developing countries increases, there will be opportunities for rapid tests and advanced tests that are now emerging as local healthcare systems become more sophisticated.

A report from Kalorama Information (Rockville, MD, USA), publisher of research in medical markets, presents the challenges that BRIC countries face entering the IVD market. The report also explores the opportunities that specific developing countries offer to IVD companies. Kalorama attempts to add some realistic aspects of working in a foreign country that are more qualitative in nature.

A number of reports on the BRIC and emerging markets have been published. Most of these focus on quantitative data such as number of labs, hospitals, product registration regulations, and import taxes and conditions. Too many of them tend to present only a growth scenario without presenting the challenges the nations face.

Some of the same trends–growing middle class, mix of infectious and noncommunicable diseases, and government supported healthcare–are prevalent in many countries in Eastern Europe and Africa. Kalorama provides three non-BRIC nations: Turkey, Poland, and Nigeria as examples of where IVD may flourish in the future.

Author of the report, Shara Rosen, RT, MBA, commented, "It is now recognized that it's the low- and middle-income countries that face the greatest burden of chronic diseases such as diabetes, heart disease, and cancer. As markets in industrialized countries begin to mature, IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and a growing demand for quality medical care."

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare, as well as a full range of custom research services.

Related Links:

Kalorama Information


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.